177Lu-DOTATATE
![Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==)
Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy
... As noted above, the most common intervention for reducing kidney irradiation from radiolabeled somato- statin analogues is to competitively block their tubular reabsorption by co-infusion of basic amino-acids. Alter- ...
9
Method dependence, observer variability and kidney volumes in radiation dosimetry of 177Lu-DOTATATE therapy in patients with neuroendocrine tumours
... On all 30 patients, SPECT/CT of the abdomen was performed 1, 4 and 7 days after administration of the first therapeutic cycle of 7.4 GBq 177 Lu-DOTATATE. Imaging was performed on an Infinia (International General ...
13
Radiation exposure of the spleen during 177Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume
... Although a dose-dependent relationship may exist between the mean absorbed dose to the spleen and the blood cell count, there are several other factors that contribute to the haematological response during 177 ...
9
A novel planar image-based method for bone marrow dosimetry in 177Lu-DOTATATE treatment correlates with haematological toxicity
... A total of 46 patients at Sahlgrenska University Hospital, who were diagnosed with ad- vanced neuroendocrine tumours, were included in this retrospective study. The study was approved by the Regional Ethics Review Board ...
12
Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)
... nausea and vomiting) and one patient developed a gastroduodenal ulcer. The interval between PRRT and RE was not mentioned, but patients were only referred for RE in case they had progressive disease (i.e. salvage ...
11
Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
... The quality-of-life assessment was conducted at base- line and after 3 months of the last cycle administered to the patient. Most of the patients reported symptomatic relief and improved general well-being after the ...
10
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
... The percentage retained activity at the time of discharge was measured retrospectively for PRRT patients who were administered 177 Lu-DOTATATE supplied by two different com- panies, following both inpatient and ...
12
Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy
... The variability of the sensitivity over a range of activities was also evaluated and proved to be lower than 5% from 0.1 to 100 kBq of 177 Lu. Over 100 kBq, count loss due to dead time becomes significant (Fig. 7). The ...
15
SPECT image segmentation for estimation of tumour volume and activity concentration in 177Lu-DOTATATE radionuclide therapy
... Background: Dosimetry in radionuclide therapy has the potential to allow for a treatment tailored to the individual patient. One therapeutic radiopharmaceutical where patient-specific dosimetry is feasible is 177 ...
17
Feasibility and accuracy of single time point imaging for renal dosimetry following 177Lu-DOTATATE (‘Lutate’) therapy
... However, given the large average deviations of methods 1 and 2 from the gold standard estimates made when using complete data sets (59% and 30%, respectively), it may be that the use of [r] ...
9
Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life
... radiopharmaceutical, 177Lu- DOTA-Tyr3-octreotate (177Lu-Dotatate), was ...of 177Lu-Dotatate PRRT on PFS has been evaluated in numerous papers, with a general consensus reached on its ...
7
<p>Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights</p>
... Lutetium-177 Dotatate (Lutathera ® ) was FDA approved for the treatment of advanced somatostatin positive ...evaluated 177Lu- DOTATATE combined with 30 mg long-acting repeatable (LAR) versus 60 mg ...
11
Characterization of SnO2-based 68Ge/68Ga generators and 68Ga-DOTATATE preparations: radionuclide purity, radiochemical yield and long-term constancy
... Method: A sum of 123 eluates from four different 68 Ge- 68 Ga generators (iThemba Labs, Faure, South Africa) and 115 samples of the prepared radiopharmaceutical 68 Ga-DOTATATE were measured first with a dose ...
10
Delker, Andreas (2016): Investigation of models with temporal and spatial interference in image based dosimetry of 177Lu-labelled radioligand therapies. Dissertation, LMU München: Medizinische Fakultät
... We studied the effect of reducing the number of measure- ment times on the outcome of dosimetry calculations based on various multi-phase descriptions of the kidney activity following a [ 177 Lu]DOTATATE treatment ...
82
[177Lu-DOTA]0-D-Phe1-Tyr3-Octreotide (177Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study
... In progressive low- and intermedi- ate-grade GEP-NET patients, a PFS of 34.5 months and a high tumour control rate (objective response 54.2%, stable disease 45.8%) indicate that 177 [r] ...
10
Accuracy of 177Lu activity quantification in SPECT imaging: a phantom study
... 3 Quantification errors for phantom inserts with different shapes and volumes scanned in cold water and error distribution ( b ) for both scatter correction methods, TEW and APDI ( b )..[r] ...
20
Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody
... Specific tumor targeting was observed, with low background tissue and organ uptake except for the kidneys, which was the main limitation for a clinical application of nanobody-based t[r] ...
13
Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate
... Peptide receptor radionuclide therapy (PRRT) is an ef- fective treatment option for patients with an inoperable neuroendocrine tumour (NET) or with metastatic dis- ease [1, 2]. Approximately 80 % of patients with NET ...
10
Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT
... Regarding diagnostic accuracy, we report the low sen- sitivities of CT imaging for myocardial metastasis detec- tion as evaluated by expert reading of a case-control cohort. We characterized the imaging appearance in ...
7
AAZTA5/AAZTA5-TOC: synthesis and radiochemical evaluation with 68Ga, 44Sc and 177Lu
... Rapid and quantitative 44 Sc-AAZTA 5 complex formation (both AATZA 5 and AAZTA 5 -TOC) at room temperature with low precursor amounts of five nmol demon- strate that the AAZTA 5 structur[r] ...
10